Kite Pharma (KITE)

[crudeoil24]

$80.00+ >> This week!!!!!

[crudeoil24]

Multi-day runner!!!!!

[crudeoil24]

KITE > “We are grateful to the study participants and investigators who have made this important research possible. What started at the NCI over a decade ago with the pioneering work of Steven A. Rosenberg, M.D., Ph.D., has evolved into a technology that has the potential to fundamentally change the outlook of patients with cancer. For patients with aggressive NHL, every day matters and a new treatment option like KTE-C19 is desperately needed,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. “I am proud of what we have achieved to date and excited to apply our advanced learnings from ZUMA-1 to our ongoing clinical development programs to bring continued innovation to patients and the scientific community at large.”

ZUMA-1 is supported in part by funding from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program®.

[MARINO]

Thanks

[blackbandit]

good call marino. I don't hold kite but I hold their supplier for that trial, BLFS. GLTU

[MARINO]

Marino was righr $$$$

[MARINO]

Marino in at $53.80
KITE Is Oversold

[Crusader]

Positive close today:

Stars are lining up!

The last 7 days are positive! CHART LINK:

http://ih.advfn.com/stock-market/NASDAQ/kite-pharma-inc-KITE/chart/streaming?mode=html5

[Crusader]

Another quiet board on IHUB,

Pharma does not pay dividends! ;))

http://ih.advfn.com/p.php?pid=nmona&article=71920583

Let's give it a few months for this news link above to play out.

THEN KABOOM!!!

[Crusader]

Constructive though anemic price action today. eom

[Fibanotch]

ceo, didn't brush his teeth...going down to 43

[Crusader]

Make that 3 PR's on Monday: 6-6-16:

http://finance.yahoo.com/news/kite-pharma-highlight-key-data-120000155.html

Sorry about the date error.

Anyway, the European presentations are very soon. What news will come to light on this T cell engineering?

To answer that question the is ONE PR today:

6-8-16 PR teasers from KITE:

"...We are excited to showcase the progress we have made with personalized T-cell immuno-oncology for people with refractory lymphoma and to share our understanding of the outcomes for this patient population who have limited or no treatment options,” said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “These data are important to advance our novel breakthrough personalized treatments and ultimately address critical unmet medical needs.”

Updated data from Phase 1 of Kite’s ZUMA-1 study of KTE-C19 in patients with chemorefractory non-Hodgkin lymphoma (NHL) will be presented in an oral presentation. An additional oral presentation will feature data from the SCHOLAR-1 study, the first and largest meta-analysis of outcomes in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive and common form of NHL that is difficult to treat. Patients with chemorefractory DLBCL have not responded to prior treatment with chemotherapy or have relapsed within a year after autologous stem cell transplantation.

Data from a Phase 1-2a study evaluating anti-CD19 CAR T-cell therapy after low-dose chemotherapy in people with advanced lymphoma will also be highlighted in an oral presentation. This study is being conducted as part of a Cooperative Research and Development Agreement (CRADA) between Kite and the National Cancer Institute (NCI).

Kite also recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) has granted access to its newly established Priority Medicines (PRIME) regulatory initiative for KTE-C19 in the treatment of patients with refractory DLBCL. PRIME provides early and enhanced regulatory support to optimize regulatory applications and speed up the review of medicines that address a high unmet need. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.

Oral presentations at the 2016 EHA Annual Congress..."

[Crusader]

Last year's CNBC video of CEO:

http://video.cnbc.com/gallery/?video=3000391199

I will post today's interview later today or tomorrow.

Compare the interviews and decide
,

[Crusader]

CEO on CNBC said today:

They are producing product to supply patients after final approval.

And said their technology applicable to cancers beyond blood cancer.

Good news for many patients suffering.

[Crusader]

3 Press Releases today:

For example:

http://ih.advfn.com/p.php?pid=nmona&article=71659923

Anyone!

[Crusader]

CEO interviewed on CNBC just now,

Price popping some.

Where is everyone!

[stocktrademan]

$KITE recent news/filings

bearish optionable 63.85

## source: finance.yahoo.com

Fri, 11 Dec 2015 18:58:23 GMT ~ Juno Therapeutics is on the Brink of Curing Cancer


read full: http://finance.yahoo.com/tumblr/blog-juno-is-on-the-brink-of-curing-cancer-190141949.html
*********************************************************

Fri, 11 Dec 2015 13:31:13 GMT ~ Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

[at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:KITE) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 543,750 ...

read full: http://www.noodls.com/view/13614909897BB6C50D73CA838921059FFB0BB944
*********************************************************

Fri, 11 Dec 2015 13:00:00 GMT ~ Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

[GlobeNewswire] - SANTA MONICA, Calif. -- Kite Pharma, Inc. today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 543,750 ...

read full: http://finance.yahoo.com/news/kite-pharma-announces-full-exercise-130000289.html
*********************************************************

Fri, 11 Dec 2015 11:03:31 GMT ~ KITE PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151211/kite8-k.html
*********************************************************

Thu, 10 Dec 2015 13:27:18 GMT ~ Kite Pharma Announces Pricing of Public Offering of Common Stock

[at noodls] - SANTA MONICA, Calif., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price ...

read full: http://www.noodls.com/view/7B93F55649036683D58214B25DE2AF64DE848134
*********************************************************

$KITE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$KITE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/KITE/company-info
Ticker: $KITE
OTC Market Place: Not Available
CIK code: not found
Company name: Kite Pharma, Inc.
Incorporated In: USA

$KITE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$KITE extra dd links

Company name: Kite Pharma, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KITE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KITE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KITE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KITE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KITE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/news - http://finance.yahoo.com/q/h?s=KITE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KITE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KITE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KITE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KITE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KITE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KITE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Kite+Pharma%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Kite+Pharma%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Kite+Pharma%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KITE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KITE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KITE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KITE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KITE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KITE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KITE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KITE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KITE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KITE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KITE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KITE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KITE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KITE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KITE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KITE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KITE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KITE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KITE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KITE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KITE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KITE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KITE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KITE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KITE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KITE



$KITE DD Notes ~ http://www.ddnotesmaker.com/KITE

[rand0m]

come on push push push!!!

[KingDMC]

+7% $62.88

[north40000]

Be wary of the conference call set for Monday morning.

[TheFinalCD]

KITE HIGHER THAN JUNO DERP~!



http://seekingalpha.com/news/2605595-kite-pharma-rides-junos-celgene-deal-coattails-shares-up-9-percent-after-hours

[homdance]

Kite Pharma Inc (NASDAQ:KITE) initiated by Mizuho at "buy." $90.00 price target.

Kite Pharma Inc (NASDAQ:KITE)'s price target was raised by Canaccord Genuity from $51.00 to $90.00. "buy" rating.

[homdance]

Looks like may be setting up cup&handle here going back to end of January?

[Exodus]

watch CBMG - they are in the same biotech sector!
news will be out on wednesday! great potential - like KITE!

[md1225]

http://seekingalpha.com/article/2953756-wall-streets-current-play-immunotherapy-of-cancer

[llessurK]

Yeah, KITE flys easily like most low float biotechs. $5+ intraday moves are not uncommon on this one.

Today was a good day to scoop up discounted bios.

[mudslog]

Should rocket back to 70 real soon

[llessurK]

KITE nice bounce off the 50-Day Moving Average on the daily here:



IBB selling off today. Could be a good time to load up on this one.

[DewDiligence]

KITE is already talking publicly about product pricing: #msg-109963319.

[mudslog]

If the market cap was like facebook, this would be $6400 a share...and they cure cancer.

[Viperciara]

KITE before you knew they were going to be worth $3 Billion.
Uses this stem cell companies product! http://www.neostem.com/media/press-releases/news-item/pct-kite-pharma/

[stocktrademan]

$KITE DD Notes ~ http://www.ddnotesmaker.com/KITE

bullish
added to Nasdaq Biotech Index

$KITE recent news/filings

## source: finance.yahoo.com

Tue, 16 Dec 2014 13:41:06 GMT ~ Kite Pharma Added to the NASDAQ Biotechnology Index

[at noodls] - SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products ...

read full: http://www.noodls.com/view/F01A300521C6BA3F2A244F95115ACE29B110E4A9
*********************************************************

Tue, 16 Dec 2014 13:00:00 GMT ~ Kite Pharma Added to the NASDAQ Biotechnology Index

[GlobeNewswire] - SANTA MONICA, Calif. -- Kite Pharma, Inc., ,a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, announced ...

read full: http://finance.yahoo.com/news/kite-pharma-added-nasdaq-biotechnology-130000596.html
*********************************************************

Mon, 15 Dec 2014 22:46:00 GMT ~ IPO Calendar: Year Wrapping Up With Juno, OnDeck IPOs


read full: http://news.investors.com/121514-730614-juno-ondeck-among-four-year-end-ipos.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Mon, 15 Dec 2014 14:42:36 GMT ~ The Hottest Biotech IPO of the Year Arrives This Week


read full: http://finance.yahoo.com/tumblr/blog-the-hottest-biotech-ipo-of-the-year-arrives-this-144238865.html
*********************************************************

Fri, 12 Dec 2014 15:04:00 GMT ~ Watch A Man Tell How Killer T-Cells Eradicated His Cancer


read full: http://www.forbes.com/sites/matthewherper/2014/12/12/watch-a-man-tell-how-killer-t-cells-eradicated-his-cancer/?partner=yahootix
*********************************************************


$KITE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$KITE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/KITE/company-info
Ticker: $KITE
OTC Market Place: Not Available
CIK code: not found
Company name: Kite Pharma, Inc.
Incorporated In: USA


$KITE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$KITE extra dd links

Company name: Kite Pharma, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KITE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KITE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KITE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KITE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KITE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/news - http://finance.yahoo.com/q/h?s=KITE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KITE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KITE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KITE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KITE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KITE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KITE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KITE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Kite+Pharma%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Kite+Pharma%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Kite+Pharma%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KITE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KITE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KITE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KITE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KITE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KITE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KITE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KITE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KITE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KITE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KITE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KITE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KITE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KITE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KITE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KITE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KITE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KITE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KITE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KITE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KITE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KITE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KITE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KITE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KITE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KITE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KITE



$KITE DD Notes ~ http://www.ddnotesmaker.com/KITE

[MinnieM]

Up another $1. 1.06 in fact.

[MinnieM]

KITE daily chart:

[expediter13]

A bunch of manipulation going on here. Wonder how high it can go. They have SOMETHING, but when will they make money...

[undog]

short this in the am @33.00!!! you will make bank!!

[ClayTrader]

* * $KITE Video Chart 10-02-14 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $KITE Video Chart 8-27-14 * *

Link to Video - click here to watch the technical chart video

[strategicinvest]

This is well known since Monday night thus during after hour trading it went to $31. Now, the recent news is what I posted hence the market reacts accordingly I presume, GLTA.

[beambe]

NEW YORK (TheStreet) -- Kite Pharma (KITE_) continued to surge Tuesday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.

Kite treated patients with its an anti-CD19 chimeric antigen receptor (CAR) T cell therapy called KTE-C19. Eight of 13 patients with Advanced B cell malignancies showed complete remissions, while four showed partial remissions. The total result was a 92% objective response rate.

Furthermore, four of seven patients with chemotherapy-refractory diffuse large B-cell Lymphoma showed complete remissions. Three of these cases are ongoing, while one is ongoing after 22 months.








http://www.thestreet.com/story/12857173/1/why-kite-pharma-kite-stock-continues-to-surge-today.html?puc=CNBC&cm_ven=CNBC

[strategicinvest]

Still sitting on the sideline after reading this news...

Kite Pharma Inc. (KITE): The biotech firm late Monday said 12 out of 13 patients in an early-to-mid-stage clinical trial showed some form of remission from Non-Hodgkins lymphoma after receiving the company's drug candidate.

By Angela Johnson and William Watts , MarketWatch
NEW YORK (MarketWatch) -- These are stocks making notable moves on Tuesday:
Gainers
ANN Inc. (ANN): The women's retailer has hired J.P. Morgan to explore a potential sale.
DSW Inc. (DSW): The discount shoe-retailer reported stronger-than-expectedsecond-quarter results early Tuesday.
Hewlett-Packard Co. (HPQ) : The computer company is recalling hazardous power cords Tuesday.
Amazon.com Inc. (AMZN): The online retailer confirmed the purchase of live-streaming service Twitch late Monday. Amazon is also making moves to more directly challenge Google in online ads.
Bedrocan Cannibis Corp. : The Canadian medical marijuana producer has been flying high since it started trading in Toronto on Monday.
Kite Pharma Inc. (KITE): The biotech firm late Monday said 12 out of 13 patients in an early-to-mid-stage clinical trial showed some form of remission from Non-Hodgkins lymphoma after receiving the company's drug candidate.
Digital Ally Inc. (DGLY): Interest in the wearable-camera company's products has been on the rise after the fatal police shooting of unarmed teenager Michael Brown in the St. Louis suburb of Ferguson . Price action in the stock has seen big swings over recent days.
Decliners
Orbitz Worldwide Inc. (OWW): American Airlines Group Inc. (AAL) has withdrawn its fares as well of those of US Airways , which it owns, from the online travel website.
Burger King Worldwide Inc. (BKW): The fast-food chain confirmed plans to take over Canadian coffee-and-doughnut chain Tim Hortons Inc. (THI) and move its headquarters across the border. Billionaire investor Warren Buffett is helping with the financing. But moving to Canada to cut taxes may not work as well for individuals.
Best Buy Co. Inc. (BBY): The consumer-electronics retailer's outlook was soft.
Trina Solar Ltd. ADS(TSL): The Chinese manufacturer of solar-power modules swung to a profit in the second quarter, but its solar-module shipments fell just shy of expectations.
Tickers to Watch
Apple Inc. (AAPL): The iPhone and iPad maker failed to set a fifth straight record close. Last week, Apple set a post-stock-split record of $101.32 . Apple announced Monday it will replace defective iPhone 5 batteries.
Facebook Inc. (FB): The social-networking site said it is cracking down on "click-bait," citing user dissatisfaction with misleading headlines.
- Angela Johnson ; 415-439-6400; [e-mail]
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
08-26-14 1406ET

[Criz]

Yowzaa!!!!!

[beambe]

Market capitalization of 1.02 billion

[beambe]

only patience we could run slowly over 60 dollars

[Criz]

Price target anyone? Resistance points? Good entry price???
Or have I missed the boat?
Thx,
Tidalgal

[beambe]

http://www.kitepharma.com/c/pipeline/index.php

[beambe]

Pipeline

[beambe]

which is a Money maschiene

[TheFinalCD]

AUG 26, 2014 KITE PHARMA TO PRESENT AT CITI 9TH ANUAL BIOTECH....

http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=867677

[beambe]

-Kite Pharma's lead cancer immunotherapy shows promise in study

Aug 25 (Reuters) - Drug developer Kite Pharma Inc said its experimental cancer immunotherapy showed potential in treating patients with an aggressive form of blood cancer, in an early-stage study.

The company's shares rose as much as 49.5 percent in extended trading.

Kite's lead therapy, KTE-C19, is being developed to fight non-Hodgkin's lymphoma, a cancer that originates in the lymph nodes.

In one arm of the study, funded by Kite and conducted by National Cancer Institute, 15 patients were given the therapy. Of the 13 patients eligible for evaluation, cancer symptoms disappeared completely in eight patients and partially in four, the company said.

The therapy involves genetically modifying a patient's cells to target a protein found on the surface of some lymphoma and leukemia cells.

Kite said it planned to seek in the fourth quarter the U.S. Food and Drug Administration's approval for further clinical testing of the therapy.

Santa Monica, California-based Kite's shares closed at $22.30 on the Nasdaq on Monday.

Up to Monday's close, the stock had risen about 31 percent since it debuted in June.

(Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)

http://www.cnbc.com/id/101945759